Shots:

• The ongoing P-IIa ANTT201 trial will evaluate the safety- PK- immunogenicity & antiviral activity of Arbutus’ AB-729 (RNAi therapeutic targeted hepatocytes)- Antios’ ATI-2173 (ASPIN liver-targeted) & Viread vs PBO in 10 patients in a ratio (8:2) with chronic HBV infection. The study is expected to be initiated in H2’21
• ATI-2173 + Viread (qd) will be administered for 90 days while AB-729 (SC) will be administered on Day 28 & Day 90. Post 90 days- subjects will be followed up for additional 6mos.
• Antios will be responsible for the costs of adding single cohort to its ongoing clinical trial while Arbutus will be responsible to manufacture & supply AB-729

  | Ref: Globe Newswire | Image: Globe Newswire